A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe
文献类型：期刊论文
| 作者 | Hu,Liangning1; Li,Bo2; Chen,Gege1; Song,Dongliang1; Xu,Zhijian2 ; Gao,Lu1; Xi,Mengyu2; Zhou,Jinfeng1; Li,Liping1; Zhang,Hui1
|
| 刊名 | Journal of Experimental & Clinical Cancer Research
 |
| 出版日期 | 2020-06-09 |
| 卷号 | 39期号:1 |
| 关键词 | Multiple myeloma Drug-resistance DNA damage response Cell cycle |
| DOI | 10.1186/s13046-020-01597-9 |
| 通讯作者 | Zhu,Weiliang(wlzhu@simm.ac.cn) ; Shi,Jumei(shijumei@tongji.edu.cn) |
| 英文摘要 | AbstractBackgroundDCZ3301, a novel aryl-guanidino compound previously reported by our group, exerts cytotoxic effects against multiple myeloma (MM), diffused large B cell lymphoma (DLBCL), and T-cell leukemia/lymphoma. However, the underlying mechanism of its action remains unknown.MethodsWe generated bortezomib (BTZ)-resistant cell lines, treated them with various concentrations of DCZ3301 over varying periods, and studied its effect on colony formation, cell proliferation, apoptosis, cell cycle, DNA synthesis, and DNA damage response. We validated our results using in vitro and in vivo experimental models.ResultsDCZ3301 overcame bortezomib (BTZ) resistance through regulation of the G2/M checkpoint in multiple myeloma (MM) in vitro and in vivo. Furthermore, treatment of BTZ-resistant cells with DCZ3301 restored their drug sensitivity. DCZ3301 induced M phase cell cycle arrest in MM mainly via inhibiting DNA repair and enhancing DNA damage. Moreover, DCZ3301 promoted the phosphorylation of ATM, ATR, and their downstream proteins, and these responses were blocked by the ATM specific inhibitor KU55933.ConclusionsOur study provides a proof-of-concept that warrants the clinical evaluation of DCZ3301 as a novel anti-tumor compound against BTZ resistance in MM. |
| 语种 | 英语 |
| 出版者 | BioMed Central |
| WOS记录号 | BMC:10.1186/S13046-020-01597-9 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/280143]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Zhu,Weiliang; Shi,Jumei |
| 作者单位 | 1.Shanghai Tenth People’s Hospital, Tongji University School of Medicine; Department of Hematology 2.Shanghai Institute of Materia Medica, Chinese Academy of Sciences; CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center 3.Tongji University Cancer Center, Tongji University |
| 推荐引用方式 GB/T 7714 | Hu,Liangning,Li,Bo,Chen,Gege,et al. A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe[J]. Journal of Experimental & Clinical Cancer Research,2020,39(1). |
| APA | Hu,Liangning.,Li,Bo.,Chen,Gege.,Song,Dongliang.,Xu,Zhijian.,...&Shi,Jumei.(2020).A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe.Journal of Experimental & Clinical Cancer Research,39(1). |
| MLA | Hu,Liangning,et al."A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe".Journal of Experimental & Clinical Cancer Research 39.1(2020). |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。